Diet-Dependent and Diet-Independent Hemorheological Alterations in Celiac Disease: A Case-Control Study

Zsolt Szakács, MD1,2, Beáta Csiszár, MD2,3, Máté Nagy4, Nelli Farkas, PhD1,4, Péter Kenyeres, MD, PhD2,3, Adrienn Erős, MD, PhD1,5, Alizadeh Hussain, MD, PhD2,6, Katalin Márta, MD, PhD1,2, Andrea Szentesi, PhD1, Margit Tőkés-Füzesi, MD, PhD7, Tímea Berki, MD, PhD, ScD8, Áron Vincze, MD, PhD2,9, Kálmán Tóth, MD, PhD, ScD2,3, Péter Hegyi, MD, PhD, ScD1,2 and Judit Bajor, MD, PhD9

INTRODUCTION: Hemorheology is the study of the flow properties of the blood and its elements, which, together with natural anticoagulants, are important determinants of cardiovascular events. This study aimed to assess hemorheological and natural anticoagulant profiles of patients with celiac disease (CeD) comprehensively.

METHODS: Our study is a case-control study (registered under ISRCTN49677481) comparing patients with CeD with age- and sex-matched control subjects (1:1). We measured erythrocyte deformability (ED) at high (3–30 Pa) and low shears (0.3–3 Pa), erythrocyte aggregation, whole blood viscosity, plasma viscosity, and natural anticoagulants (protein C, protein S, and antithrombin activity). Adherence to gluten-free diet was estimated through dietary interview and urine gluten immunogenic peptide (urine GIP) detection.

RESULTS: After matching, we analyzed the data of 100 study participants. ED at high shears was impaired in CeD ($P < 0.05$ for all shears, confirmed by random forest analysis) independently of findings on CeD-specific serological assessment and urine GIP detection but slightly dependently on dietary adherence ($P = 0.025$ for 30 Pa shear). ED at low shears seemed to be impaired only in urine GIP+ CeD patients ($P < 0.05$ for all comparisons with urine GIP− CeD patients and control subjects). All parameters describing erythrocyte aggregation and whole blood viscosity were shifted toward a prothrombotic direction in patients with CeD with poor dietary adherence compared with those with good dietary adherence. Plasma viscosity and activity of natural anticoagulants did not differ across groups.

DISCUSSION: We observed diet-dependent and diet-independent prothrombotic hemorheological alterations in CeD, which can contribute to the elevated cardiovascular risk. The untoward metabolic changes during gluten-free diet, which can further aggravate hemorheological status, may indicate the implementation of prevention strategies.
INTRODUCTION
Celiac disease (CeD) is a chronic, immune-mediated disorder, which develops on gluten exposure in genetically susceptible individuals (1). CeD affects about 1% of the population; nevertheless, its prevalence is still increasing (2).

The disease carries the risk of severe complications including but not restricted to nutritional deficiencies, metabolic bone disease, and malignant tumors (1). Besides, cardiovascular (CV) comorbidities should be highlighted. A meta-analysis (2012) of population-based studies suggested an increased 1.19-fold risk of CV-related deaths for patients with CeD (3), confirmed by a recent (2020) population-based Swedish cohort study (4). The increased CV risk can be explained with several pathophysiological mechanisms. Prothrombotic alterations include malabsorption (vitamin K deficiency with subsequent protein C and protein S deficiency, or vitamin B12/B9 deficiency with subsequent hyperhomocysteinemia), thrombophilic antibodies, accelerated atherosclerosis, endothelial and platelet dysfunction, comorbid conditions (e.g., antiphospholipid syndrome), subclinical chronic inflammation, and genetics (5,6). Energy density and nutrient composition of gluten-free diet (GFD) often deviate from the optimal (7–10), raising concerns about a variety of modifiable CV risk factors to change unfavorably (11).

Besides the factors mentioned above, the hemorheological profile should be taken into account when potential prothrombotic alterations are investigated. Hemorheology (in other words, blood rheology) is the study of the flow properties of the blood and its elements. Hemorheological indicators, such as hematocrit (HTC), whole blood viscosity (WBV), plasma viscosity (PV), erythrocyte deformability (ED), and erythrocyte aggregation (EA), play fundamental roles in the maintenance of microcirculation (12–14). Besides, partly through increased endothelial shear stress (15), an altered hemorheological profile has long been known to be an essential determinant of thrombogenesis (16,17) and was reported in various immune-mediated diseases including systemic lupus erythematosus (18,19) and rheumatoid arthritis (19,20). Hemorheological indicators are extensively studied in inflammatory bowel disease; reports indicated (sometimes, activity dependent) alterations of ED, EA, fibrinogen, and PV in both Crohn’s disease and ulcerative colitis (21–27). Nevertheless, little (or rather no) attention has been paid to hemorheology in CeD. Similarly, natural anticoagulants (protein C, protein S, and antithrombin), the physiological inhibitors of the coagulation cascade, and thrombogenesis were never investigated in patients with CeD in a comparative study.

Our aim was the comprehensive evaluation of hemorheological and natural anticoagulant profiles of patients with CeD with particular focus on the effects of dietary adherence to explore alterations which can contribute to the elevated CV risk.

METHODS
The study was approved by the Regional and Local Research Ethics Committee (University of Pecs, Pecs, Hungary; Ref No. 6917) and registered in the ISRCTN Registry under registration number ISRCTN49677481. Full technical details of the protocol are published elsewhere (28). This report follows the STROBE Statement (29).

Design, setting, and eligibility
Our study is a single-center observational study with a case-control design. Adults (aged ≥18 years) were recruited consecutively from the gastroenterology outpatient clinic of our

Table 1. Hemorheology-related terms and measurements

| Parameter (abbreviation) | Measurement (abbreviation or symbol, unit) | Definition | Unfavorable alterationa |
|--------------------------|-------------------------------------------|------------|------------------------|
| Erythrocyte deformability (ED) | Elongation index (EI, no unit) | Change in the shape of red blood cells at high (from EI3Pa to EI3Pa in this study) and low shear stresses (from EI3Pa to EI3Pa in this study) (shown in Figure 1 inlet) | ↓ |
| Erythrocyte aggregation (EA) | Aggregation index (AI, %) | Integral in the change of light intensity 10 s after disaggregation | ↑ |
| | Aggregation half-time (t1/2, s) | The time required for achieving half of the maximal aggregation after disaggregation | ↓ |
| | Threshold shear rate (γ, s−1) | Lowest shear that can maintain complete disaggregation | ↑ |
| Viscosity | Whole blood viscosity (WBV, mPa·s) | An intrinsic property of fluid related to the internal friction of adjacent fluid layers sliding past one another (i.e., the measure of a fluid’s resistance) | ↑ |
| | Plasma viscosity (PV, mPa·s) | | ↑ |

*aRegarding thrombus formation. AI, t1/2, and γ were measured with Laser-assisted Optical Rotational Cell Analyzer (LORCA; R&R Mechatronics, Hoorn, the Netherlands). EI was measured with laser-diffraction ektacytometry with a LORCA, and WBV and PV were measured with Brookfield DV-III Ultra LV Programmable rotational viscometer (Brookfield Engineering Labs, Middleboro, MA) at mid-shear (90 s−1).
academic hospital between June 2017 and May 2018. Cases were patients with biopsy-confirmed CeD diagnosed according to the current guidelines (30,31). Control subjects were individuals in whom CeD was excluded by the treating gastroenterologist specialist (30,31). Exclusion criteria from the study are detailed in the prestudy protocol (28).

Outcomes
Outcomes included hemorheological parameters (describing HTC, WBV, PV, fibrinogen, ED, and EA) and the activity of natural anticoagulants (antithrombin, protein C, and protein S).

Flow and timing
Potential participants with a definitive diagnosis were screened for eligibility by a gastroenterologist specialist. If consented to participate, detailed medical history was obtained, and medical files were revised; then, the questionnaires were administered by the same person. The visit ended with a dietary interview, followed by blood and urine collection in our central laboratory unit.

Questionnaires, laboratory measurements, and dietary interview
We used a thrombophilia questionnaire to assess arterial and venous thrombotic risk factors (for the items of the questionnaire, see Supplementary Digital Content 1, http://links.lww.com/CTG/A418) and the Gastrointestinal Symptom Rating Scale to assess the severity of gastrointestinal symptoms (32).

Laboratory tests were performed from venous blood as detailed in the prestudy protocol (28). Hemorheology-related terms and measurements are detailed in Table 1. We adhered to the guidelines proposed by the International Expert Panel for Standardization of Hemorheological Methods during the tests (33). Urine gluten immunogenic peptides (urine GIPs) were measured by a point-of-care test according to the test’s user guide (iVYCHECK GIP Urine, Biomedal, Spain).

In patients with CeD, dietary adherence was estimated through a dietary interview conducted by an accredited dietitian who judged adherence on a visual analog scale between 1 (regular gluten-containing diet) and 10 (perfect GFD). The same person ensured that control subjects did not follow a GFD.

Subgroup analysis
Patients with CeD were divided by CeD-specific serology (based on tissue transglutaminase antibody [Tg]-IgA/IgG and endomyosal antibody [EMA] IgA/IgG levels with the cutoff from the test’s user guide), by estimated dietary adherence based on dietary interview (scores <8 points were chosen to indicate poor dietary adherence), and by the results of urine GIP measurement (interpreted according to the test’s user guide). CeD-specific serology rather reflects the intensity of the ongoing immune response and is sensitive to detect major dietary transgressions, whereas urine GIP positivity rather reflects gluten intake of the past 2–3 days (34).

Sample size and data analysis
Because hemorheological indicators were never determined in CeD, we planned to recruit 100 age- and sex-matched participants (1:1 ratio) in the first phase to determine further target numbers for the second phase (28). Completing the first phase, we realized that to reach the level of significance for the observed mean differences between patients with CeD and control subjects at α = 0.05 and β = 0.80, we should recruit an unfeasible number of subjects (>1,000 patients for EA indicators, 247 patients for PV, and 289 patients for WBV per group), so that we decided to stop the study for futility.

In univariate analysis, we used the Welch, Mann-Whitney, χ², and Fisher tests; one-way ANOVA (with the Tukey post hoc test), Kruskal-Wallis test (with the Mann-Whitney post hoc test) and Bonferroni correction (where appropriate). In multivariate analysis, we used the random forest method to determine and graphically display the relative importance of each predictor. During prediction, 100 random forests with 500 trees in each were grown using conditional inference method to avoid bias toward dependent predictors and overfitting (35).

The calculations were performed with IBM SPSS for Windows (version 25.0 statistical software package; Armonk, NY: IBM Corp.) and R statistical language (version 3.6, party statistical software package; R Core Team, Vienna, Austria).

## Table 2. Clinical characteristics of the study population

|                      | Celiac group (n = 50) | Control group (n = 50) |
|----------------------|-----------------------|------------------------|
| Age (mean; median [min–max], yr) | 40.0; 40.0 (18.0–75.0) | 40.4; 41.0 (19.0–74.0) |
| Females (n, %)       | 33 (66.0)             | 37 (74.0)              |
| Venous thrombotic event in the history (n, %) | 0 (0.0)               | 1 (2.0)                |
| Arterial thrombotic event in the history (n, %) | 1 (2.0)               | 0 (0.0)                |
| Thrombotic events in first-degree relatives (n, %) | 14 (28.0)             | 12 (24.0)              |
| Current smoker (n, %) | 9 (18.0)              | 6 (12.0)               |
| Alcohol consumption (≥7 units/wk) (n, %) | 3 (6.0)               | 4 (8.0)                |
| Chronic alcohol abuse (n, %) | 3 (6.0)               | 2 (4.0)                |
| Body mass index (mean; median [min–max], kg/m²) | 23.6; 23.0 (16.4–40.5) | 24.1; 23.7 (18.0–39.2) |
| Hypertension (n, %)  | 13 (26.0)             | 12 (24.0)              |
| Peripheral arterial disease (n, %) | 0 (0.0)               | 1 (2.0)                |
| Type 2 diabetes mellitus (n, %) | 3 (6.0)               | 3 (6.0)                |
| Lower limb varicose veins (n, %) | 14 (28.0)             | 11 (22.0)              |
| Surgery (≥1 yr) (n, %) | 7 (14.0)              | 7 (14.0)               |
| Immobilization (≥14 d) (n, %) | 1 (2.0)               | 0 (0.0)                |
| Travel by plane, bus, or car (≥6 hr continuously; ≥14 d) (n, %) | 3 (6.0) | 5 (10.0) |
| Oral contraceptives (n, % of females) | 8 (24.2) | 10 (27.0) |

Statistical comparison was not performed if the event number was ≤1 for categorical variables, P ≥ 0.05 for all comparisons otherwise.
Table 3. Biochemical characteristics of the study population

|                          | Celiac group  | Control group | P value |
|--------------------------|---------------|---------------|---------|
|                          | (n = 50)      | (n = 50)      |         |
| Total cholesterol (mmol/L) | 4.55; 4.45 (2.70–6.60) | 5.32; 5.05 (3.20–9.30) | 0.001   |
| HDL cholesterol (mmol/L)  | 1.43; 1.39 (0.65–2.97) | 1.70; 1.63 (0.77–3.09) | 0.006   |
| LDL cholesterol (mmol/L)  | 2.98; 3.02 (1.13–4.97) | 3.50; 3.30 (0.45–7.85) | 0.015   |
| Non–HDL cholesterol (mmol/L) | 3.14; 3.14 (1.13–5.27) | 3.61; 3.42 (1.98–7.67) | 0.032   |
| Triglyceride (mmol/L)     | 1.47; 1.31 (0.46–3.74) | 1.69; 1.32 (0.60–7.18) | 0.456*  |
| Creatinine (umol/L)       | 71.6; 68.5 (39.0–110.0) | 72.8; 68.5 (49.0–105.0) | 0.668   |
| Carbohydrate (mmol/L)     | 4.2; 4.1 (2.2–7.3) | 4.5; 4.3 (2.2–7.9) | 0.257   |
| Total bilirubin (umol/L)  | 8.1; 7.9 (2.7–20.0) | 9.5; 8.1 (2.1–24.5) | 0.120*  |
| Aspartate transaminase (U/L) | 25.6; 19.0 (10.0–200.0) | 22.0; 20.0 (10.0–89.0) | 0.806*  |
| Alanine transaminase (U/L) | 24.1; 18.0 (9.0–158.0) | 21.7; 18.0 (8.0–60.0) | 0.901*  |
| ALP (U/L)                 | 74.3; 68.0 (36.0–269.0) | 67.9; 67.5 (35.0–108.0) | 0.696   |
| γ-GT (U/L)                | 23.1; 16.0 (10.0–94.0) | 26.1; 16.0 (7.0–210.0) | 0.825*  |
| Total protein (g/L)b      | 74.5; 74.7 (62.4–93.0) | 75.3; 74.7 (67.7–85.2) | 0.445   |
| Albumin (g/L)             | 48.2; 47.8 (37.8–56.6) | 49.2; 49.1 (43.9–57.8) | 0.182   |
| Ultrasensitive CRP (mg/L) | 3.4; 1.8 (0.0–23.5) | 2.3; 1.4 (0.0–10.1) | 0.342*  |
| ESR (mm/hr)               | 9.0; 4.0 (1.0–46.0) | 6.1; 5.0 (1.0–27.0) | 0.808*  |
| Prothrombin time (s)      | 11.4; 11.3 (9.6–14.0) | 11.2; 11.2 (9.8–13.2) | 0.252   |
| Thrombin time (s)         | 14.5; 14.6 (12.6–16.9) | 14.3; 14.2 (12.0–17.4) | 0.213   |
| APTT (s)                  | 28.6; 28.3 (23.3–36.1) | 30.1; 28.7 (19.0–72.9) | 0.176   |
| INR                       | 0.99; 0.98 (0.84–1.23) | 0.98; 0.97 (0.86–1.09) | 0.460   |
| White blood cells (G/L)   | 7.3; 6.8 (3.7–16.2) | 6.7; 6.4 (4.1–12.4) | 0.165   |
| Neutrophil granulocytes (%)| 59; 59 (41–83) | 58; 58 (43–74) | 0.353   |
| Neutrophil granulocytes (G/L) | 4.4; 4.2 (1.7–13.4) | 3.9; 3.6 (1.8–9.2) | 0.134   |
| Lymphocytes (%)           | 30; 29 (9–45) | 32; 33 (16–47) | 0.171   |
| Lymphocytes (G/L)         | 2.1; 2.0 (1.2–4.2) | 2.1; 2.1 (1.1–3.9) | 0.947   |
| Monocytes (%)             | 7.3; 7.0 (2.6–11.5) | 7.4; 7.4 (4.2–10.7) | 0.773   |
| Monocytes (G/L)           | 0.52; 0.48 (0.15–1.14) | 0.50; 0.47 (0.18–0.99) | 0.469   |
| Eosinophil granulocytes (%)| 2.5; 2.0 (0.3–8.5) | 1.8; 1.5 (0.0–7.8) | 0.023   |
| Eosinophil granulocytes (G/L) | 0.18; 0.14 (0.01–0.60) | 0.11; 0.10 (0.00–0.47) | 0.003   |
| Basophil granulocytes (%) | 0.77; 0.60 (0.30–6.00) | 0.70; 0.70 (0.20–1.90) | 0.487   |
| Basophil granulocytes (G/L) | 0.05; 0.04 (0.02–0.15) | 0.05; 0.04 (0.01–0.09) | 0.659   |
| Red blood cells (T/L)     | 4.8; 4.8 (3.8–5.8) | 4.9; 4.8 (3.9–5.8) | 0.441   |
| Hemoglobin (g/L)          | 140; 138 (99–169) | 144; 142 (115–176) | 0.149   |
| MCV (fL)                  | 84.8; 84.6 (65.6–97.6) | 85.3; 85.3 (70.3–94.8) | 0.603   |
| MCH (pg)                  | 29.0; 29.4 (20.3–32.8) | 29.5; 29.7 (22.9–33.4) | 0.252   |
| MCHC (g/L)                | 343; 343 (309–361) | 346; 346 (321–364) | 0.118   |
RESULTS

Characteristics of the study population
A total of 162 consecutive potential participants were screened for eligibility, 126 of which were included in the study (for flowchart, see Supplementary Digital Content 2, http://links.lww.com/CTG/A419). After matching patients by age and sex (1:1, n = 100), groups were similar in baseline characteristics except for cholesterol profile, eosinophil cell count, and red blood cell distribution width (Tables 2 and 3). For comorbid conditions and medications of the study participants, see Supplementary Digital Content 3, http://links.lww.com/CTG/A420.

Table 3. (continued)

|                          | Celiac group (n = 50) | Control group (n = 50) | P value |
|--------------------------|-----------------------|------------------------|---------|
| RDW (%CV)                | 13.3; 12.6 (11.8–19.8) | 12.6; 12.6 (11.0–14.5) | 0.022   |
| Platelets (G/L)          | 297; 283 (179–601)    | 282; 277 (126–432)     | 0.309   |
| Homocysteine (μmol/L)    | 9.0; 8.3 (5.1–13.7)   | 8.7; 7.7 (4.4–42.9)    | 0.040a  |
| Vitamin B₁₂ (ng/L)       | 450; 450 (156–785)    | 396; 424 (192–613)     | 0.076a  |

Boldface type indicates a statistically significant difference between the groups.

Values were generated with the Mann-Whitney test; all the other values were generated with the Welch test.

Values are given in the following format: mean; median [min–max]. Missing data due to unsuccessful measurement(s): blood counts – 1 patient with CeD, erythrocyte sedimentation rate – 2 patients with CeD, coagulatory parameters – 1 patient with CeD and 1 control subject; vitamin B₁₂ level – 3 patients with CeD and 7 control subjects. γ-GT, gamma-glutamyl transferase; ALP, alkaline phosphatase; ALT, alanine aminotransferase; APTI, activated partial thromboplastin time; AST, aspartate aminotransferase; CeD, celiac disease; CRP, C-reactive protein; CV, cardiovascular; ESR, erythrocyte sedimentation rate; HDL, high-density lipoprotein; INR, international normalized ratio; LDL, low-density lipoprotein; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; RDW, red cell distribution width.

Figure 1. Erythrocyte deformability at different shears (ektacytogram) in patients with celiac disease and control subjects. The horizontal axis indicates the different shears from 0.3 to 30 Pa; the vertical axis shows the elongation index (EI, calculated based on the equation presented in the inlet). Measurements of EI were performed with LORCA. P values < 0.05 are highlighted with bold, and were generated with the Mann-Whitney test. Inlet: model for erythrocyte deformation at different shears describing the transition from biconcave to ellipsoid shape. In the equation, A and B represent the long and short axes of the cells, respectively, as indicated with blue arrows in the figure. EI, elongation index (no. of patients = 100).
median of 1.50 points on the Gastrointestinal Symptom Rating Scale.

Control subjects attended a regular checkup (n = 18), were admitted for investigation (n = 16) or mandatory occupational health assessment (n = 16). None of them followed a GFD, and all tested negative for both tTG and EMA.

**Hemorheological parameters in patients with celiac disease vs control subjects**

Patients with CeD had impaired ED at high shears compared with controls (P, 0.05 for the comparisons at 5 shears from 3 to 30 Pa; Figure 1), whereas we observed no significant difference in markers of EA, WBV, PV, and fibrinogen between the groups (for table, see Supplementary Digital Content 4, http://links.lww.com/CTG/A421, which describes the results of comparisons). After correction for 34 clinical and biochemical variables (including CeD vs control status), random forest analysis indicated that CeD is an important determinant of ED at high shears from 5.33 to 30 Pa (Figure 2), unlike at lower shears or regarding EA, HTC, WBV, and PV (for figure, see Supplementary Digital Content 5, http://links.lww.com/CTG/A422, which displays the results of random forest analysis). The most important predictors of hemorheological parameters overlapped those known from the literature, ensuring the validity of random forest analysis.

**Association of dietary adherence and serological findings with hemorheological parameters**

Supplementary Digital Content 6 (http://links.lww.com/CTG/A423) summarizes raw data and statistics on findings on serological assessment, dietary interview, and urine GIP detection.

ED at high shears seemed to be impaired both in patients with CeD who were seropositive and seronegative (Figure 3a) and both in patients with CeD with poor and good dietary adherence (Figure 3B) compared with control subjects. However, ED at high shears did not differ significantly between seropositive and seronegative patients with CeD (Figure 3a), whereas those with good adherence had better ED only at E30pa compared with those with poor adherence (which was not supported by the results of urine GIP measurement) (Figure 3b,c). These suggest that the impairment in ED at high shears is independent of the EMA/tTG-mediated immune response and only partly dependent on dietary adherence (favoring a better GFD). Interestingly, ED at low shears did not differ across groups irrespective of findings on serological assessment and dietician-reported dietary adherence (Figure 3d,e). Opposingly, urine GIP+ CeD patients had significantly impaired ED compared with urine GIP− CeD patients and control subjects (Figure 3f) without a difference between urine GIP− CeD patients and control subjects. These results suggest that ED at low shears may not be influenced by EMA/tTG-mediated immune response but may be influenced by other effects of gluten or related proinflammatory reaction.

EA seemed to be significantly impaired in patients with CeD with poor adherence compared with those with good adherence and control subjects (Figure 4). The association applies to AI, t1/2, and G consistently (adjusted P values <0.01 for all; for figure, see Supplementary Digital Content 7, http://links.lww.com/CTG/A424), suggesting prothrombotic alterations in patients with CeD with poor adherence. However, seropositive patients did not differ from seronegative ones so that EMA/tTG-mediated immune response is unlikely explaining the results.

Although WBV seemed to be lower in patients with CeD with good adherence compared with patients with CeD with poor adherence, none of the groups differed significantly from control subjects. HTC, WBV, and PV did not seem to be different substantially across the groups. For figures, see Supplementary Digital Content 7, http://links.lww.com/CTG/A424.
Natural anticoagulants

Measuring the endogenous anticoagulants, we observed no difference in protein C, protein S, and antithrombin activity between the CeD and control groups (Table 4), while CeD proved not to be an important predictor in random forest analysis. Dividing patients by findings on serological assessment, dietician-reported dietary adherence, or by results of urine GIP measurement did not reveal any difference across the groups.

DISCUSSION

We identified impaired ED in CeD, which proved to be independent of findings on serological assessment and dependent, though only partly, on dietary adherence. Also, we found pro-thrombotic alterations in markers describing EA (AI, t1/2, and g), especially in patients with poor dietary adherence. In addition, we observed lower WBV in patients with CeD with good dietary adherence compared with those with poor adherence. These findings contribute to the understanding of the mechanism of increased CV risk in CeD despite the absence of traditional risk factors: those with CeD have a lower body mass index, less smoking, lower diastolic blood pressure, and a lower level of cholesterol (36,37).

ED at high shears (3–30 Pa) rather models the pressure in the small arteries and arterioles, whereas ED at low shears (0.3–3 Pa) rather models that in the microcirculation. Rigid red blood cells (RBCs) may increase total peripheral resistance and require a higher pressure gradient to squeeze through capillaries. ED is determined mainly by membrane fluidity and cytoplasmatic viscosity, but extracorpuscular factors, such as splenic function or mechanical stress in the narrow capillaries, may have an irreversible impact on RBCs’ membrane (14,38). A potential explanation for the impaired ED in CeD might be due to functional hyposplenism (affecting 16–77% of patients with CeD) when rigid RBCs are no longer removed from the circulation (39,40). Another option may be increased intracellular oxidative stress and reduced nitric oxide production (41). ED might be influenced by comorbidities and lifestyle factors as well (38), however, matching balanced major covariates between the groups. Of note, patients with CeD had lower total and low-density lipoprotein cholesterol levels in our study and previous research (37). Membrane cholesterol content is known to correlate with ED inversely (i.e., the higher the cholesterol, the more rigid the RBCs are) (42). Surprisingly, patients with CeD had impaired ED despite the lower cholesterol level (which is the so-called opposing bias supporting a cause-effect relationship), implying that from a hemorheological aspect, a lower cholesterol level should be considered optimal in CeD. This highlights the need for optimization of calorie density and suboptimal lipid profile of GFD.

Reports showed that an impaired ED is often found with CV diseases (43–45). In our study, at high shears, ED was impaired compared with control irrespective of seropositivity or dietary adherence, whereas patients with good dietician-reported adherence had better ED only at 30 Pa compared with those with poor dietary adherence (based on the dietary interview). This suggests that the impairment is independent on EMA/TG-mediated
immune reactions and only loosely dependent on gluten intake. Interestingly, GIP+ CeD patients, compared with GIP− CeD patients, had impaired ED at low shears, whereas we did not observe any difference across the groups if the patients were divided by findings on serological assessment or by the results of dietary interview. Theoretically, gluten, alone or via the activation of an immune response, may cause endothelial damage/activation via oxidative stress or other mechanisms (41,46,47), which can...
Table 4. Natural anticoagulants

|                        | Celiac group (n = 50) | Control group (n = 50) | P value |
|------------------------|-----------------------|------------------------|---------|
| Antithrombin activity (%) | 120.28 ± 14.39        | 121.84 ± 14.16         | 0.589   |
| Protein C activity (%) | 124.60 ± 33.72        | 134.30 ± 32.47         | 0.146   |
| Protein S activity (%) | 98.40 ± 29.44         | 104.02 ± 30.35         | 0.338   |

Values are given in mean ± SD. P values were generated with the Welch test after logarithmic transformation in the case of antithrombin and protein S activity. Missing data due to unsuccessful measurement(s) in the case of 1 patient with CeD and 1 control subject.

Conclusions

In this study, we observed lower activity of natural anticoagulants in patients with CeD compared with control subjects. The differences were statistically significant for protein C and protein S compared with control subjects, the difference did not attain statistical significance, nor in subgroup analyses by serological assessment or dietician-reported dietary adherence. Interestingly, lupus anticoagulant was confirmed positive in 6 patients with CeD and 7 control subjects, and only sporadic cases were positive for antibodies against β2-glycoprotein, prothrombin, and cardiolipin, not supporting the theory about thrombophilic autoantibodies in CeD.

Strengths of the study include its novelty: to our best knowledge, no comparative study has assessed the hemorheological and natural anticoagulant profile of patients with CeD. In addition, the rigorous, standard methodology and comprehensive analysis should be mentioned. Our multimodal approach of dietary adherence included a dietary interview, celiac-specific serology, and measurement of urine GIP. Nevertheless, we must mention several limitations of the evidence. Prospective cohort studies recording the changes from diagnosis until follow-up visit provide better evidence of a cause-effect relationship. Per the recent guidelines, we do not perform follow-up biopsy routinely, and, consequently, we were unable to test the associations between intestinal histology and test results. However, mucosal changes do not necessarily reflect dietary adherence (1,55) and are not necessarily associated with long-term CV outcomes (56).

Our conclusions are rather generalizable to younger and treated patients with CeD since 47 of 50 cases were on GFD ≥1 year (as reflected by the restored homocysteine level). It must be noted, however, that the length of GFD seems not important regarding our outcomes based on the results of random forest analyses.

We found impaired ED in CeD, which seemed to be independent of findings on serological assessment and only partially dependent on dietary adherence. Patients with CeD with poor dietary adherence exhibited prothrombotic alterations of EA, whereas HTC, WBV, PV, and natural anticoagulants seemed not to be substantially affected in CeD irrespective of dietary adherence. These findings should be validated in prospective cohort studies.

The unfavorable alterations of ED and EA can contribute to the elevated CV risk and highlight the importance of CV prevention in CeD during GFD in which good dietary adherence is of utmost importance. As metabolic syndrome has become a threat in CeD and its components (obesity, hypertension, diabetes mellitus, and dyslipidemia) can further aggravate hemorheological status, lifestyle changes (e.g., regular exercise and energy-optimized diet) or even pharmacological interventions (e.g., polyphenols and statins) may help to mitigate hemorheological alterations and thereby reduce CV risk. Randomized studies are called for to validate the clinical implications of our findings.

CONFLICTS OF INTEREST

Guarantor of the article: Judit Bajor, MD, PhD.
Specific author contributions: Z.S., P.H., and J.B. conceptualized the study and drafted the manuscript. J.B. and Á.V. formally screened and consented study participants. Z.S., Á.E., B.C., M.N., and K.M. administered the questionnaires and collected and validated the data. Measurements were performed and interpreted by B.C., P.K., and K.T. regarding hemorheological parameters, by A.H. and M.T.F. regarding hemostatic parameters, and by T.B. regarding immunological indicators. N.F. performed the statistical analysis. A.S. and K.M. coordinated the project. Á.V., K.T., P.H., and J.B. supervised the project. All authors revised the draft of the manuscript.
Financial support: This study was supported by an Economic Development and Innovation Operative Programme Grant (GINOP 2.3.2-15-2016-00048) and a Human Resources Development Operative Programme Grant (EFOP-3.6.2-16-2017-00006) of the National Research, Development and Innovation Office, Hungary, and by the ÚNKP-18-3-1 and ÚNKP-19-3-1 New National Excellence Program of the Ministry of Human Capacities, Hungary.
Potential competing interests: None to report.
Trial registration number: ISRCTN49677481, ISRCTN Registry.
ACKNOWLEDGEMENTS

We express our gratitude to Dr Barbara Sándor, Kornélia F. Tapasztoné, and Beáta Horváth for the assistance in the measurement and interpretation of hemorheological and hemostatic laboratory parameters and to Ibiolya Veczák for conducting the dietary interviews.

Study Highlights

WHAT IS KNOWN
- Risk of thrombotic events is higher among patients with celiac disease.
- Hemorheological and hemostatic alterations are potential contributors to cardiovascular events.

WHAT IS NEW HERE
- Erythrocyte deformation is impaired in patients with celiac disease, which is only partly dependent on dietary adherence.
- Erythrocyte aggregation is shifted toward a prothrombotic direction in patients with celiac disease with poor dietary adherence.

TRANSLATIONAL IMPACT
- The prothrombotic hemorheological alterations highlight the importance of cardiovascular prevention in celiac disease.
- Cardiovascular risk factors (e.g., metabolic syndrome) developing during gluten-free diet may further aggravate hemorheological status.
- Good dietary adherence can improve hemorheological alterations, but some parameters are independent of diet.

REFERENCES

1. Al-Toma A, Volta U, Auricchio R, et al. European Society for the Study of Coeliac Disease (EsslCD) guideline for coeliac disease and other gluten-related disorders. United Eur Gastroenterol J 2019;7:583–613.
2. Singh P, Arora A, Strand TA, et al. Global prevalence of celiac disease: Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2018;16:823–36.e2.
3. Tio M, Cox MR, Eslick GD. Meta-analysis: Coeliac disease and the risk of all-cause mortality, any malignancy and lymphoid malignancy. Aliment Pharmacol Ther 2012;35:540–51.
4. Lebwohl B, Green PFR, Söderling J, et al. Association between celiac disease and mortality risk in a Swedish population. JAMA 2020;323:1277–85.
5. Dunic I, Martin S, Salfiti N, et al. Deep venous thrombosis and bilateral pulmonary embolism revealing silent celiac disease: Case report and review of the literature. Case Rep Gastrointest Med 2017;2017;5236918.
6. Lerner A, Blank M. Hypercoagulability in celiac disease: An update. Autoimmun Rev 2014;13:118–41.
7. Fry L, Madden AM, Fallaize R. An investigation into the nutritional composition and cost of gluten-free versus regular food products in the UK. J Hum Nutr Diet 2018;31:108–20.
8. Miranda J, Lasa A, Bustamante MA, et al. Nutritional differences between a gluten-free diet and a diet containing equivalent products with gluten. Plant Foods Hum Nutr 2014;69:182–7.
9. Taetsch A, Das SK, Brown C, et al. Are gluten-free diets more nutritious? An evaluation of self-selected and recommended gluten-free and gluten-containing dietary patterns. Nutrients 2018;10:1881.
10. Vici G, Belli I, Blondi M, et al. Gluten free diet and nutrient deficiencies: A review. Clin Nutr 2016;35:1236–41.
11. Potter MDE, Brienesse SC, Walker MM, et al. Effect of the gluten-free diet on cardiovascular risk factors in patients with celiac disease: A systematic review. J Gastroenterol Hepatol 2018;33:781–91.
12. Baskurt OK, Meiselman HJ. Erythrocyte aggregation: Basic aspects and clinical importance. Clin Hemorheol Microcirc 2013;53:23–37.
13. Peters SA, Woodward M, Rumley A, et al. Plasma and blood viscosity in the prediction of cardiovascular disease and mortality in the Scottish Heart Health Extended Cohort Study. Eur J Prev Cardiol 2017;24:161–7.
14. Schmid-Schönbein H. Microrheology of erythrocytes, blood viscosity, and the distribution of blood flow in the microcirculation. Int Rev Physiol 1976:9:1–62.
15. Cecchi E, Giglioli C, Valente S, et al. Role of hemodynamic shear stress in cardiovascular disease. Atherosclerosis 2011;214:249–56.
16. Ernst E, Koenig W. Hemorheology, thrombogenesis, and atherosclerosis. Semin Thromb Hemost 1993;19:99–103.
17. Toth A, Papp J, Rabai M, et al. The role of hemorheological factors in cardiovascular medicine. Clin Hemorheol Microcirc 2014;56:197–204.
18. Ernst E, Heim A, Meurer M, et al. Blood rheology in lupus erythematosus. Ann Rheum Dis 1991;50:710–2.
19. Santos MJ, Pedro LM, Canhão H, et al. Hemorheological parameters are related to subclinical atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis patients. Atherosclerosis 2011;219:821–6.
20. Luquita A, Uri L, Svetaz MJ, et al. Erythrocyte aggregation in rheumatoid arthritis: Cell and plasma factor’s role. Clin Hemorheol Microcirc 2009;41:49–56.
21. Akman T, Akarsu M, Akpinar H, et al. Erythrocyte deformability and oxidative stress in inflammatory bowel disease. Dig Dis Sci 2012;57:458–64.
22. Lobo AJ, Jones SC, Juby LD, et al. Plasma viscosity in inflammatory bowel disease. J Clin Pathol 1992;45:54–7.
23. Maharshak N, Arbel Y, Shapiro I, et al. Increased strength of erythrocyte aggregates in blood of patients with inflammatory bowel disease. Inflamm Bowel Dis 2009;15:707–13.
24. Moran A, Jones A, Asquith P. Laboratory markers of colonicoscopy activity in ulcerative colitis and Crohn’s colitis. Scand J Gastroenterol 1995;30:356–60.
25. Novacek G, Vogelsang H, Genser D, et al. Changes in blood rheology caused by Crohn’s disease. Eur J Gastroenterol Hepatol 1996;8:1089–93.
26. Yakar T, Cosar AM, Gökturek HS, et al. Plasma viscosity: A potential predictor of both medical treatment response and clinical stage of ulcerative colitis. Ann Ital Chir 2016;87:531–43.
27. Zilberman L, Rogowski O, Rozenblat M, et al. Inflammation-related erythrocyte aggregation in patients with inflammatory bowel disease. Dig Dis Sci 2005;50:677–83.
28. Szakács Z, Csisszár B, Kenyeres P, et al. Haemorheological and haemostatic alterations in coeliac disease and inflammatory bowel disease in comparison with non-celiac, non-IBD subjects (HERMES): A case-control study protocol. BMJ Open 2019;9:e026315.
29. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration. PLoS Med 2007;4:e297.
30. Rubio-Tapia A, Hill ID, Kelly CP, et al. ACG clinical guidelines: Diagnosis and management of celiac disease. Am J Gastroenterol 2013;108:636–77.
31. Husby S, Koletzko S, Korponay-Szabó IR, et al. European society for pediatric gastroenterology, hepatology, and nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012;54:136–60.
32. Svedlund J, Sjödin I, Dottevall G. GSRs: A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988;33:129–34.
33. Baskurt OK, Boynard M, Cokelet GC, et al. New guidelines for hemorheological laboratory techniques. Clin Hemorheol Microcirc 2009;42:75–97.
34. de Lourdes Moreno M, Rodríguez-Herrera A, Sousa C, et al. Biomarkers to monitor gluten-free diet compliance in celiac patients. Nutrients 2017;9:46.
35. Strobl C, Boulesteix AL, Kneib T, et al. Conditional variable importance in random forests. BMC Bioinformatics 2008;9:307.
36. Brar P, Kwon GY, Holleran S, et al. Change in lipid profile in celiac disease: Beneficial effect of gluten-free diet. Am J Med 2006;119:786–90.
37. West J, Logan RF, Hill PG, et al. Seroprevalence, correlates, and characteristics of undetected coeliac disease in England. Gut 2003;52:960–5.
41. Moretti S, Mrakic-Sposta S, Roncoroni L, et al. Oxidative stress as a biomarker for monitoring treated celiac disease. Clin Transl Gastroenterol 2018;9:157.

42. Kohno M, Murakawa K, Yasunari K, et al. Improvement of erythrocyte deformability by cholesterol-lowering therapy with pravastatin in hypercholesterolemic patients. Metabolism 1997;46:287–91.

43. Fornal M, Korbut RA, Krolczyk J, et al. Left ventricular geometry and rheological properties of erythrocytes in patients at cardiovascular disease risk. Clin Hemorheol Microcirc 2009;43:203–8.

44. Penco M, Romano S, Dagiianti A Jr, et al. Modifications of whole blood filterability during acute myocardial infarction. Clin Hemorheol Microcirc 2006;22:153–9.

45. Yoshida H, Satoh K, Takamatsu S. Platelet-activating factor acetylhydrolase in red cell membranes. Does decreased activity impair erythrocyte deformability in ischemic stroke patients? Stroke 1993;24:14–8.

46. Diaz-Castro J, Muriel-Neyra C, Martin-Masot R, et al. Oxidative stress, DNA stability and evoked inflammatory signaling in young celiac patients consuming a gluten-free diet. Eur J Nutr 2019;59:1577–1584.

47. Dolfini E, Elli L, Roncoroni L, et al. Damaging effects of gliadin on three-dimensional cell culture model. World J Gastroenterol 2005;11:5973–7.

48. Mika P, Spodaryk K, Cencora A, et al. Red blood cell deformability in patients with claudication after pain-free treadmill training. Clin J Sport Med 2006;16:335–40.

49. Szapary L, Horvath B, Marton Z, et al. Short-term effect of low-dose atorvastatin on haemorheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia. CNS Drugs 2004;18:165–72.

50. Cartwright HJ, Pockley AG, Galloway JH, et al. The effects of dietary omega-3 polyunsaturated fatty acids on erythrocyte membrane phospholipids, erythrocyte deformability and blood viscosity in healthy volunteers. Atherosclerosis 1985;55:267–81.

51. Magyar K, Halmosi R, Palfi A, et al. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc 2012;50:179–87.

52. Radosinska J, Horvathova M, Frimmel K, et al. Acute dark chocolate ingestion is beneficial for hemodynamics via enhancement of erythrocyte deformability in healthy humans. Nutr Res 2017;39:69–75.

53. Weng X, Roederer GO, Beaulieu R, et al. Contribution of acute-phase proteins and cardiovascular risk factors to erythrocyte aggregation in normolipidemic and hyperlipidemic individuals. Thromb Haemost 1998;80:903–8.

54. Soare AM, Popa C. Deficiencies of proteins C, S and antithrombin and activated protein C resistance–their involvement in the occurrence of Arterial thromboses. J Med Life 2010;3:412–5.

55. Szakács Z, Mátrai P, Hegyi P, et al. Younger age at diagnosis predisposes to mucosal recovery in celiac disease on a gluten-free diet: A meta-analysis. PLoS One 2017;12:e0187526.

56. Szakács Z, Gede N, Gyöngyi Z, et al. A call for research on the prognostic role of follow-up histology in celiac disease: A systematic review. Front Physiol 2019;10:1408.

Open Access This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.